Skip to content
Disclosery

NOVO HOLDINGS A/S

Follow

13F filer, CIK 1388325, HELLERUP, Denmark

NOVO HOLDINGS A/S reported $1,287,677,054 across 24 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 71.3% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001388325-26-000007

Period
2025-12-31
Reported value
$1.29B
Holdings
24
Top 10 weight
71.3%
New
1
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MPLTnew+3,686,622$64.8M
BNadded+1,165,415$53.5M
FDMTadded+1,650,737$12.4M
APGEadded+70,000$5.28M
ELVNadded+53,740$828K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VTIexited-1,038,550-$341M
MERUS N Vexited-750,000-$70.6M
RXRXexited-7,929,835-$38.7M
ASMLreduced-31,890-$34.1M
ZBIOreduced-550,000-$20M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001388325-26-000007, largest first. % of portfolio is the value over $1,287,677,054, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BNBROOKFIELD CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,491,230 shares; 2024Q4: 2,798,830 shares; 2025Q1: 2,330,830 shares; 2025Q2: 2,330,830 shares; 2025Q3: 2,330,830 shares; 2025Q4: 3,496,245 shares 3,496,245$160M12.46%+1,165,415Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,549,900 shares; 2024Q4: 5,000,000 shares; 2025Q1: 5,350,000 shares; 2025Q2: 5,350,000 shares; 2025Q3: 5,350,000 shares; 2025Q4: 5,350,000 shares 5,350,000$133M10.31%0Timeline
ASMLASML HLDG NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 133,336 shares; 2024Q4: 165,836 shares; 2025Q1: 165,836 shares; 2025Q2: 165,836 shares; 2025Q3: 145,836 shares; 2025Q4: 113,946 shares 113,946$122M9.47%-31,890Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,500,000 shares; 2024Q4: 1,500,000 shares; 2025Q1: 1,500,000 shares; 2025Q2: 1,500,055 shares; 2025Q3: 1,264,028 shares; 2025Q4: 1,264,028 shares 1,264,028$99.8M7.75%0Timeline
CRMSALESFORCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 368,560 shares; 2024Q4: 293,901 shares; 2025Q1: 272,801 shares; 2025Q2: 330,187 shares; 2025Q3: 330,187 shares; 2025Q4: 330,187 shares 330,187$87.5M6.79%0Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,000,000 shares; 2024Q4: 960,215 shares; 2025Q1: 1,275,000 shares; 2025Q2: 1,550,000 shares; 2025Q3: 1,625,000 shares; 2025Q4: 1,625,000 shares 1,625,000$75.6M5.87%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,385,000 shares; 2024Q4: 2,250,000 shares; 2025Q1: 2,250,300 shares; 2025Q2: 2,380,000 shares; 2025Q3: 2,380,000 shares; 2025Q4: 2,380,000 shares 2,380,000$74.1M5.75%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,686,622 shares 3,686,622$64.8M5.03%newTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,150,000 shares; 2024Q4: 1,600,000 shares; 2025Q1: 2,214,967 shares; 2025Q2: 2,250,000 shares; 2025Q3: 2,000,000 shares; 2025Q4: 1,450,000 shares 1,450,000$52.6M4.09%-550,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,725,000 shares; 2024Q4: 1,725,000 shares; 2025Q1: 1,725,000 shares; 2025Q2: 1,725,000 shares; 2025Q3: 1,750,000 shares; 2025Q4: 1,750,000 shares 1,750,000$48.6M3.77%0Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 449,392 shares; 2025Q3: 500,000 shares; 2025Q4: 570,000 shares 570,000$43M3.34%+70,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 750,000 shares; 2025Q1: 915,000 shares; 2025Q2: 916,160 shares; 2025Q3: 916,160 shares; 2025Q4: 916,160 shares 916,160$42.3M3.28%0Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 490,000 shares; 2024Q4: 490,000 shares; 2025Q1: 490,000 shares; 2025Q2: 660,000 shares; 2025Q3: 660,000 shares; 2025Q4: 660,000 shares 660,000$39.2M3.05%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,505,315 shares; 2024Q4: 1,520,627 shares; 2025Q1: 1,872,142 shares; 2025Q2: 1,872,142 shares; 2025Q3: 1,942,142 shares; 2025Q4: 1,942,142 shares 1,942,142$39.1M3.03%0Timeline
BABAALIBABA GROUP HLDG LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 500,827 shares; 2024Q4: 452,327 shares; 2025Q1: 372,327 shares; 2025Q2: 372,327 shares; 2025Q3: 257,327 shares; 2025Q4: 257,327 shares 257,327$37.7M2.93%0Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 724,666 shares; 2024Q4: 724,666 shares; 2025Q1: 724,666 shares; 2025Q2: 680,000 shares; 2025Q3: 200,000 shares; 2025Q4: 200,000 shares 200,000$34.8M2.7%0Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 963,663 shares; 2024Q4: 1,000,000 shares; 2025Q1: 1,200,000 shares; 2025Q2: 1,200,000 shares; 2025Q3: 1,200,000 shares; 2025Q4: 1,200,000 shares 1,200,000$32.6M2.53%0Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,500,000 shares; 2024Q4: 1,500,000 shares; 2025Q1: 1,950,000 shares; 2025Q2: 2,000,000 shares; 2025Q3: 2,000,000 shares; 2025Q4: 3,650,737 shares 3,650,737$27.4M2.13%+1,650,737Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,961,317 shares; 2025Q4: 1,961,317 shares 1,961,317$24.6M1.91%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,084,432 shares; 2025Q3: 1,426,260 shares; 2025Q4: 1,480,000 shares 1,480,000$22.8M1.77%+53,740Timeline
VALNVALNEVA SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 2,375,000 shares; 2025Q3: 2,345,000 shares; 2025Q4: 2,305,000 shares 2,305,000$20.3M1.58%-40,000Timeline
LNZALANZATECH GLOBAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 158,148 shares; 2025Q4: 158,148 shares 158,148$2.18M0.17%0Timeline
MQMARQETA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 441,558 shares; 2024Q4: 441,558 shares; 2025Q1: 441,558 shares; 2025Q2: 441,558 shares; 2025Q3: 441,558 shares; 2025Q4: 441,558 shares 441,558$2.1M0.16%0Timeline
IOBTQIO BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,354,449 shares; 2024Q4: 3,354,449 shares; 2025Q1: 3,354,449 shares; 2025Q2: 3,354,449 shares; 2025Q3: 2,512,453 shares; 2025Q4: 2,512,453 shares 2,512,453$1.53M0.12%0Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VTIVANGUARD INDEX FDS1,038,550$341Mshares
MERUS N VMERUS N V750,000$70.6Mshares
RXRXRECURSION PHARMACEUTICALS IN7,929,835$38.7Mshares
DMRADAMORA THERAPEUTICS INC86,579$322Kshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001388325-26-000007 base2026-02-17acceptance time not in the bulk data set